Novel artificial intelligence-based identification of drug-gene-disease interaction using protein-protein interaction.

IF 2.9 3区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS
Y-H Taguchi, Turki Turki
{"title":"Novel artificial intelligence-based identification of drug-gene-disease interaction using protein-protein interaction.","authors":"Y-H Taguchi, Turki Turki","doi":"10.1186/s12859-024-06009-9","DOIUrl":null,"url":null,"abstract":"<p><p>The evaluation of drug-gene-disease interactions is key for the identification of drugs effective against disease. However, at present, drugs that are effective against genes that are critical for disease are difficult to identify. Following a disease-centric approach, there is a need to identify genes critical to disease function and find drugs that are effective against them. By contrast, following a drug-centric approach comprises identifying the genes targeted by drugs, and then the diseases in which the identified genes are critical. Both of these processes are complex. Using a gene-centric approach, whereby we identify genes that are effective against the disease and can be targeted by drugs, is much easier. However, how such sets of genes can be identified without specifying either the target diseases or drugs is not known. In this study, a novel artificial intelligence-based approach that employs unsupervised methods and identifies genes without specifying neither diseases nor drugs is presented. To evaluate its feasibility, we applied tensor decomposition (TD)-based unsupervised feature extraction (FE) to perform drug repositioning from protein-protein interactions (PPI) without any other information. Proteins selected by TD-based unsupervised FE include many genes related to cancers, as well as drugs that target the selected proteins. Thus, we were able to identify cancer drugs using only PPI. Because the selected proteins had more interactions, we replaced the selected proteins with hub proteins and found that hub proteins themselves could be used for drug repositioning. In contrast to hub proteins, which can only identify cancer drugs, TD-based unsupervised FE enables the identification of drugs for other diseases. In addition, TD-based unsupervised FE can be used to identify drugs that are effective in in vivo experiments, which is difficult when hub proteins are used. In conclusion, TD-based unsupervised FE is a useful tool for drug repositioning using only PPI without other information.</p>","PeriodicalId":8958,"journal":{"name":"BMC Bioinformatics","volume":"25 1","pages":"377"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653834/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Bioinformatics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12859-024-06009-9","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

The evaluation of drug-gene-disease interactions is key for the identification of drugs effective against disease. However, at present, drugs that are effective against genes that are critical for disease are difficult to identify. Following a disease-centric approach, there is a need to identify genes critical to disease function and find drugs that are effective against them. By contrast, following a drug-centric approach comprises identifying the genes targeted by drugs, and then the diseases in which the identified genes are critical. Both of these processes are complex. Using a gene-centric approach, whereby we identify genes that are effective against the disease and can be targeted by drugs, is much easier. However, how such sets of genes can be identified without specifying either the target diseases or drugs is not known. In this study, a novel artificial intelligence-based approach that employs unsupervised methods and identifies genes without specifying neither diseases nor drugs is presented. To evaluate its feasibility, we applied tensor decomposition (TD)-based unsupervised feature extraction (FE) to perform drug repositioning from protein-protein interactions (PPI) without any other information. Proteins selected by TD-based unsupervised FE include many genes related to cancers, as well as drugs that target the selected proteins. Thus, we were able to identify cancer drugs using only PPI. Because the selected proteins had more interactions, we replaced the selected proteins with hub proteins and found that hub proteins themselves could be used for drug repositioning. In contrast to hub proteins, which can only identify cancer drugs, TD-based unsupervised FE enables the identification of drugs for other diseases. In addition, TD-based unsupervised FE can be used to identify drugs that are effective in in vivo experiments, which is difficult when hub proteins are used. In conclusion, TD-based unsupervised FE is a useful tool for drug repositioning using only PPI without other information.

基于人工智能的基于蛋白质-蛋白质相互作用的药物-基因-疾病相互作用鉴定。
药物-基因-疾病相互作用的评价是鉴定有效抗病药物的关键。然而,目前,对疾病关键基因有效的药物很难确定。遵循以疾病为中心的方法,有必要确定对疾病功能至关重要的基因,并找到有效对抗它们的药物。相比之下,以药物为中心的方法包括确定药物针对的基因,然后确定这些基因对疾病至关重要。这两个过程都很复杂。使用以基因为中心的方法,我们可以识别出对疾病有效的基因,并且可以被药物靶向,这要容易得多。然而,如何在不指定目标疾病或药物的情况下识别这些基因组尚不清楚。在这项研究中,提出了一种新的基于人工智能的方法,该方法采用无监督方法,在不指定疾病或药物的情况下识别基因。为了评估其可行性,我们应用基于张量分解(TD)的无监督特征提取(FE),在没有任何其他信息的情况下,从蛋白质-蛋白质相互作用(PPI)中进行药物重新定位。基于td的无监督FE选择的蛋白质包括许多与癌症相关的基因,以及针对所选蛋白质的药物。因此,我们能够仅使用PPI识别癌症药物。由于选择的蛋白具有更多的相互作用,我们将选择的蛋白替换为枢纽蛋白,发现枢纽蛋白本身可以用于药物重定位。与枢纽蛋白只能识别癌症药物相比,基于td的无监督FE可以识别其他疾病的药物。此外,基于td的无监督FE可用于识别体内实验中有效的药物,这在使用枢纽蛋白时是困难的。总之,基于td的无监督FE是仅使用PPI而不使用其他信息的药物重新定位的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Bioinformatics
BMC Bioinformatics 生物-生化研究方法
CiteScore
5.70
自引率
3.30%
发文量
506
审稿时长
4.3 months
期刊介绍: BMC Bioinformatics is an open access, peer-reviewed journal that considers articles on all aspects of the development, testing and novel application of computational and statistical methods for the modeling and analysis of all kinds of biological data, as well as other areas of computational biology. BMC Bioinformatics is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信